肿瘤标记物在临床上被广泛使用。检测血清CA125是一种常用的早期筛查和诊断上皮性卵巢癌的临床方法，但单一特异性肿瘤标记物难以诊断上皮性卵巢癌。本研究采用组合肿瘤标记物检测方法，比较了每个肿瘤标记物单独和不同组合在诊断上皮性卵巢癌中的价值。收集了65例上皮性卵巢癌患者和29例卵巢良性疾病患者的临床数据。使用多肿瘤标记物蛋白芯片检测癌抗原125（CA125）、糖类抗原242（CA242）、α-胎球蛋白（AFP）、β-人绒毛膜促性腺激素（β-HCG）、癌胚抗原（CEA）、癌抗原199 （CA199）、神经元特异性烯醇酶（NSE）、铁蛋白、癌抗原153（CA153）和人生长激素（HGH）血清水平，并比较良性和恶性卵巢肿瘤之间的差异。采用χ2检验分析卵巢上皮癌的肿瘤标记物与临床病理特征之间的相关性。Spearman秩相关分析显示CA125表达水平与其他肿瘤标记物在上皮性卵巢癌中的相关性，以及年龄与上述10种肿瘤标记物之间的相关性。使用敏感性、特异性、阳性预测值、阴性预测值、Youden指数和诊断效能评估单个肿瘤标记物和肿瘤标记物的组合诊断价值。上皮性卵巢癌组的β-HCG、NSE、CA153和CA125水平高于卵巢良性疾病组。上皮性卵巢癌患者的血清NSE水平与患者的临床分期相关。此外，上皮性卵巢癌患者的血清中CA242、β-HCG、CEA、NSE、铁蛋白、CA153水平与CA125呈正相关(rs=0.497，P<0.001；rs=0.612，P<0.001；rs=0.358，P=0.003；rs=0.680，P<0.001；rs=0.322，P=0.009；rs=0.609，P<0.001)，β-HCG、铁蛋白、CA153水平与患者年龄呈正相关(rs=0.256，P=0.040；rs=0.325，P=0.008；rs=0.249，P=0.046)。在上皮性卵巢癌的诊断中，CA125单独检测的敏感性、Youden指数和诊断效能都高于其他9种单独检测的结果。当CA153、CA199、CA242、铁蛋白和CEA与CA125组合时，不同组合的联合检测的敏感性高于仅有的CA125。CA125+CEA和CA125+Ferritin+CEA的联合检测敏感性分别为89.2%和90.8%，诊断效能均为84.1%，高于其他组合。CA125+CEA联合检测的Youden指数为0.616，高于其他组合的结果。CA125在上皮性卵巢癌的诊断中具有较高的诊断价值。血清中组合肿瘤标记物的检测在上皮性卵巢癌中具有更高的敏感性和特异性。

Tumor markers have been widely used clinically. Detection of serum CA125 is one of the commonly used clinical methods for early screening and early diagnosis of epithelial ovarian cancer, but it is difficult to diagnose epithelial ovarian cancer with a single specific tumor marker. In this study, the combinatorial tumor marker detection method was used to compare the value of each tumor marker alone and different combinations in the diagnosis of epithelial ovarian cancer.The clinical data of patients with epithelial ovarian cancer (n=65) and ovarian benign disease (n=29) were collected. Multiple tumor marker protein chip was used to detect cancer antigen 125 (CA125), carbohydrate antigen 242 (CA242), alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-HCG), carcinoembryonic antigen (CEA), cancer antigen 199 (CA199), neuron-specific enolase (NSE), Ferritin, cancer antigen 153 (CA153), and human growth hormone (HGH) serum levels, and to compare the differences between the benign and malignant ovarian tumors. The correlation between tumor markers and clinicopathologic features for ovarian epithelial carcinoma was analyzed by χ2 test. Spearman rank analysis showed the correlation between CA125 expression level and other tumor markers in epithelial ovarian cancer and the correlation between age and the above 10 tumor markers. Sensitivity, specificity, positive predictive value, negative predictive value, Youden index, and diagnostic efficiency were used to evaluate the diagnostic value of single tumor marker and the combination of tumor markers.The levels of β-HCG, NSE, CA153, and CA125 in the epithelial ovarian cancer group were higher than those in the ovarian benign disease group. The level of NSE in the serum of patients with epithelial ovarian cancer was related to the clinical stage of patients. In addition, the levels of CA242, β-HCG, CEA, NSE, Ferritin, CA153 in the serum of patients with epithelial ovarian cancer were positively correlated with CA125 (rs=0.497, P<0.001; rs=0.612, P<0.001; rs=0.358, P=0.003; rs=0.680, P<0.001; rs=0.322, P=0.009; rs=0.609, P<0.001, respectively), and the levels of β-HCG, Ferritin, CA153 were positively correlated with the patient's age (rs=0.256, P=0.040; rs=0.325, P=0.008; rs=0.249, P=0.046, respectively). In the diagnosis of epithelial ovarian cancer, the sensitivity, Youden index, and diagnostic efficiency of CA125 detection alone were higher than the results of the other 9 separate detections. When CA153, CA199, CA242, Ferritin, and CEA were combined with CA125, the sensitivity of the combined detection of different combinations was higher than that of CA125 alone. The combined detection sensitivities of CA125+CEA and CA125+Ferritin+CEA were 89.2% and 90.8%, respectively, and the diagnostic efficiencies were both 84.1%, which were higher than those of other combinations. The Youden index of CA125+CEA joint detection was 0.616, which was higher than those of other combinations.CA125 has a high diagnostic value in the diagnosis of epithelial ovarian cancer. The detection of combined tumor markers in serum has higher sensitivity and specificity in epithelial ovarian cancer.